TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35597983

Group type: EXPERIMENTAL
Intervention: Integrated Dutch Workplace Health Promotion Program (WHPP) for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32822354

Group type: EXPERIMENTAL
Intervention: Counseling services (Group S)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No counseling experience (Group H)
Number of subjects: 105
Study: 33820636

Group type: EXPERIMENTAL
Intervention: Custodiol (4°C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ringer's solution (4°C)
Number of subjects: 90
Study: 32678879

Group type: EXPERIMENTAL
Intervention: RT alone (arm A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RT with concomitant and adjuvant TMZ (arm B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TMZ alone (arm C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RT arms (pooled arms A + B)
Number of subjects: 36
Study: 32413673

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CAG repeat polymorphism of the androgen receptor gene
Number of subjects: 120
Study: 35969885

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.45 mg/d
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 50 mg/d (patch replaced weekly)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 45
Study: 33629110

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32952837

Group type: EXPERIMENTAL
Intervention: Sugary food consumption (once or more times per day)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Good oral hygiene status
Number of subjects: 226
Study: 33764241

Group type: EXPERIMENTAL
Intervention: 2% rebamipide
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.03% tacrolimus ointment
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.05% cyclosporine
Number of subjects: 38
Study: 34909101

Group type: EXPERIMENTAL
Intervention: CPAP/NPPV
Number of subjects: 255

Group type: COMPARATOR
Intervention: HFNC
Number of subjects: 255
Study: 32594453

Group type: EXPERIMENTAL
Intervention: Liraglutide (L) therapy at a final dose of 3.0 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Liraglutide (L) therapy
Number of subjects: 72
Study: 34932102

Group type: EXPERIMENTAL
Intervention: 60 µg RSVpreF
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 120 µg RSVpreF
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 240 µg RSVpreF
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: All RSVpreF formulations
Number of subjects: 618
Study: 33689118

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle family‐based intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control condition (referral to community services)
Number of subjects: 280
Study: 32366207

Group type: EXPERIMENTAL
Intervention: Brains Ahead! Intervention
Number of subjects: 60
Study: 35555179

Group type: EXPERIMENTAL
Intervention: NED (Novel Energy Drink)
Number of subjects: 45
Study: 32202333

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non smokers
Number of subjects: 164
Study: 35320289

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship prospective audit and feedback (PAF) plus standard of care (SOC)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 530
Study: 32056983

Group type: COMPARATOR
Intervention: Outdoor aerobic training (40-min running, 4 days/week for 18 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Indoor aerobic training (40-min running, 4 days/week for 18 weeks)
Number of subjects: 32
Study: 34962176

Group type: EXPERIMENTAL
Intervention: Film therapy analysis (12 sessions, one session per week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 32939557

Group type: EXPERIMENTAL
Intervention: Plant diet (30% animal protein, 70% plant protein)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Animal diet (70% animal protein, 30% plant protein)
Number of subjects: 136

Group type: COMPARATOR
Intervention: 50/50 diet (50% animal protein, 50% plant protein)
Number of subjects: 136
Study: 32962710

Group type: EXPERIMENTAL
Intervention: Reduced imaging follow-up protocol (radiographs at week 6 and 12 on clinical indication)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Usual care (routine radiography at weeks 6 and 12)
Number of subjects: 246
Study: 35866010

Group type: EXPERIMENTAL
Intervention: Point-of-care noninterruptive clinical decision support delivering the 5-year kidney failure risk equation and recommendations for monitoring and referral.
Number of subjects: 5590

Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 5590
Study: 34731132

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 33769014

Group type: EXPERIMENTAL
Intervention: mini-PNL
Number of subjects: 245

Group type: COMPARATOR
Intervention: standard-PNL
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: PNL-Trifecta achievement
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: length of stay
Number of subjects: 245
Study: 34684442

Group type: EXPERIMENTAL
Intervention: Monitored therapy (n = 54; with an option of dose modification)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard therapy (n = 55; 500 IU vitamin D standard therapy)
Number of subjects: 109
Study: 35202942

Group type: EXPERIMENTAL
Intervention: Veterans Affairs Brief Intervention and Contact Program (VA BIC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 34350728

Group type: EXPERIMENTAL
Intervention: High serum iodide (Q1)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Low serum iodide (Q4)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Thyroglobulin (Tg)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Thyroid-stimulating hormone (TSH)
Number of subjects: 448
Study: 616117379

Group type: EXPERIMENTAL
Intervention: ranibizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Early VA response at Week 4
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Early VA response at Week 12
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: VA response at Week 4 and 12
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: VA response prediction
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Combining VA responses at Week 4 and 12
Number of subjects: 1185
Study: 32323015

Group type: EXPERIMENTAL
Intervention: 20-mm lumen apposing metal stent (LAMS)
Number of subjects: 105
Study: 34294114

Group type: EXPERIMENTAL
Intervention: Intravenous nimodipine 1–2 mg/h from the day before surgery until the fifth postoperative day and standard of care
Number of subjects: 336

Group type: COMPARATOR
Intervention: Surgery only and standard of care
Number of subjects: 336
Study: 34514682

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 3379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3379
Study: 34648011

Group type: EXPERIMENTAL
Intervention: HuCare Quality Improvement Strategy
Number of subjects: 762

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 762
Study: 32074268

Group type: EXPERIMENTAL
Intervention: Antibiotics (intravenous ertapenem 1 g once daily for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Appendectomy
Number of subjects: 530

Group type: COMPARATOR
Intervention: Antibiotics (with subsequent appendectomy)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Successful antibiotic therapy
Number of subjects: 530
Study: 34549700

Group type: EXPERIMENTAL
Intervention: Self-paced high-intensity exercise
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Self-paced moderate-intensity exercise
Number of subjects: 98

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 98
Study: 32939898

Group type: EXPERIMENTAL
Intervention: Pain assessment at weeks 0, 12, 24, 36, and 48.
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Pain intensity assessment at weeks 0, 12, 24, 36, and 48.
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Assessment of the number of pain sites at weeks 0, 12, 24, 36, and 48.
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Individual-level pain variability analysis over 48 weeks.
Number of subjects: 787
Study: 616594938

Group type: EXPERIMENTAL
Intervention: ROOTS intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (standard district practices)
Number of subjects: 29
Study: 34325887

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Phenotype group 1
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Phenotype group 2
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Phenotype group 3
Number of subjects: 7020
Study: 32417345

Group type: EXPERIMENTAL
Intervention: 36 Gy in 6 fractions, twice a week (arm 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 50 Gy in 16 fractions, four times a week (arm 2)
Number of subjects: 34
Study: 616651858

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a injected subcutaneously three times weekly (IFN beta-1a SC tiw)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta-1a injected intramuscularly once weekly (IFN beta-1a IM qw)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta-1a IM qw
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a SC tiw
Number of subjects: 0
Study: 34353237

Group type: EXPERIMENTAL
Intervention: Negative simulated voices
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Neutral simulated voices
Number of subjects: 346

Group type: COMPARATOR
Intervention: Ambient sound (control)
Number of subjects: 346
Study: 33285623

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT; n=12)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined Physical Rehabilitation (CPR; n=12)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional Training Exercises (Control; n=12)
Number of subjects: 36
Study: 32243407

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (OHAs)
Number of subjects: 108
Study: 32506992

Group type: EXPERIMENTAL
Intervention: EG1 - Treatment group designed to change sexual scripts for consensual sex
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: EG2 - Treatment group designed to promote sexual self-esteem and challenge perceived realism of pornography
Number of subjects: 324

Group type: COMPARATOR
Intervention: CG - Non-treatment control group
Number of subjects: 324
Study: 33863854

Group type: EXPERIMENTAL
Intervention: Resistance training with machines
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Resistance training with elastic tubes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Follow-up (8 weeks after training)
Number of subjects: 43
Study: 34949604

Group type: EXPERIMENTAL
Intervention: Codesigned care transition support including patient information using videos, leaflets, teach back, what-matters-to-me dialogue, coordinated rehabilitation plan, bridged e-meeting, and message system for cross-organisational collaboration.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls from other geriatric stroke and acute stroke units, and matched historic controls from a previous dataset at the intervention and control units.
Number of subjects: 0
Study: 32000816

Group type: EXPERIMENTAL
Intervention: Subperiosteal cocktail injection
Number of subjects: 0
Study: 35405714

Group type: EXPERIMENTAL
Intervention: PI-RADS v2.0
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: PI-RADS v2.1
Number of subjects: 202
Study: 33264546

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (chemoprevention group)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1049
Study: 34724323

Group type: EXPERIMENTAL
Intervention: Localized microinjections of tranexamic acid (4 mg/ml) plus Q-switched 1064 laser every 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral tranexamic acid 250 mg three times a day plus Q-switched 1064 laser every 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 32910831

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 at 1 mL/kg/h (group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 at 2 mL/kg/h (group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 24
Study: 35610125

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BaS)
Number of subjects: 2300845

Group type: COMPARATOR
Intervention: Control (no bariatric surgery)
Number of subjects: 2300845
Study: 33403921

Group type: EXPERIMENTAL
Intervention: Breath-focused digital meditation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 32792268

Group type: EXPERIMENTAL
Intervention: Lavage with tap water (G2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No lavage (G1)
Number of subjects: 22
Study: 34974959

Group type: EXPERIMENTAL
Intervention: Retromandibular approach
Number of subjects: 21

Group type: COMPARATOR
Intervention: Modified Risdon approach
Number of subjects: 21
Study: 34697586

Group type: EXPERIMENTAL
Intervention: Positive news about COVID-19
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Negative news about COVID-19
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Relaxation pause after news
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Practicing physical activity, meditation/yoga
Number of subjects: 717
Study: 32520984

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Combined Training (AT+RT)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control group (lectures about health promotion)
Number of subjects: 415
Study: 35835311

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 66
Study: 33054488

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Game Design (CBGD) based mobile game
Number of subjects: 140

Group type: COMPARATOR
Intervention: Video documentary
Number of subjects: 140
Study: 34236253

Group type: EXPERIMENTAL
Intervention: Low-concentration hypochlorous acid (HOCl) nasal irrigation
Number of subjects: 139

Group type: COMPARATOR
Intervention: Normal saline nasal irrigation
Number of subjects: 139
Study: 33685434

Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 297
Study: 34958142

Group type: EXPERIMENTAL
Intervention: 10 mg/day montelukast (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 20 mg/day montelukast (Group 3)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard treatment (Group 1)
Number of subjects: 180
Study: 33789655

Group type: EXPERIMENTAL
Intervention: Visual inspection alone
Number of subjects: 216

Group type: COMPARATOR
Intervention: Visual inspection combined with radiographic assessment
Number of subjects: 216
Study: 35131378

Group type: EXPERIMENTAL
Intervention: Collaborative care (medication therapy management and telephonic follow‐up with visits to family physicians, nurses, and dietitians)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 264

Group type: COMPARATOR
Intervention: Physician‐centric care
Number of subjects: 264
Study: 34656226

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (70 mg/m2 for 90 min) plus leucovorin (400 mg/m2 for 30 min) and fluorouracil (2400 mg/m2 for 46 h) every 2 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin only every 2 weeks
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan plus fluorouracil and leucovorin
Number of subjects: 174

Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 174
Study: 33146763

Group type: EXPERIMENTAL
Intervention: Individualised screening at 6, 12 or 24 months based on risk levels
Number of subjects: 4534

Group type: COMPARATOR
Intervention: Annual screening (control group)
Number of subjects: 4534

Group type: EXPERIMENTAL
Intervention: Individualised screening
Number of subjects: 4534
Study: 35024794

Group type: EXPERIMENTAL
Intervention: Totally Minimally Invasive Oesophagectomy (TMIE)
Number of subjects: 8640
Study: 33247380

Group type: EXPERIMENTAL
Intervention: HCQ and zinc (group I)
Number of subjects: 191

Group type: COMPARATOR
Intervention: HCQ only (group II)
Number of subjects: 191
Study: 36282079

Group type: EXPERIMENTAL
Intervention: CSL112 (2 g and 6 g)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 33730345

Group type: EXPERIMENTAL
Intervention: CPAP (PEEP 10cmH2O and FiO2 0.21) for 40 minutes
Number of subjects: 13
Study: 35268057

Group type: EXPERIMENTAL
Intervention: Ca+vitamin D supplements (S)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Low-fat dairy foods (D; 4−5 servings/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control/placebo pills (C)
Number of subjects: 97
Study: 34699903

Group type: EXPERIMENTAL
Intervention: ProTaper Next (GPT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One Shape (GOS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wave One Gold (GWO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TF Adaptive (GTF)
Number of subjects: 24
Study: 34606579

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 34980887

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (triple-strain bifidobacterial probiotic)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 33855726

Group type: EXPERIMENTAL
Intervention: Family Check‐Up (FCU) Online telehealth intervention
Number of subjects: 111
Study: 34425088

Group type: EXPERIMENTAL
Intervention: Telemedicine encounters
Number of subjects: 200

Group type: COMPARATOR
Intervention: In-person encounters
Number of subjects: 200
Study: 34458731

Group type: EXPERIMENTAL
Intervention: Early antimicrobial stewardship (AMS) team intervention (review 48 h post-MET call)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care (management of antimicrobial therapy by the treating team)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Early antimicrobial stewardship (AMS) team intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study: 33783922

Group type: EXPERIMENTAL
Intervention: Focused-attention meditation training for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 32131073

Group type: EXPERIMENTAL
Intervention: Smartphone application‐based exercise program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study: 34713365

Group type: EXPERIMENTAL
Intervention: Membracel® + LED (Photobiomodulation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Membracel® (Control)
Number of subjects: 21
Study: 32744418

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 12621

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 12621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12621
Study: 33454989

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) and Thyroid-stimulating hormone (TSH)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Free T4 (fT4)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Thyroid hormones (fT4 and TSH)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Genetic variants influencing fT4 and TSH concentrations
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: fT4
Number of subjects: 800
Study: 33866004

Group type: EXPERIMENTAL
Intervention: Irinotecan-based regimen
Number of subjects: 897

Group type: COMPARATOR
Intervention: Non-irinotecan containing regimen
Number of subjects: 897
Study: 32096470

Group type: EXPERIMENTAL
Intervention: Pure form of CBD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35764263

Group type: EXPERIMENTAL
Intervention: Pm-Pac plus cisplatin
Number of subjects: 448

Group type: COMPARATOR
Intervention: Sb-Pac plus cisplatin
Number of subjects: 448
Study: 33730804

Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 80
Study: 32434867

Group type: EXPERIMENTAL
Intervention: High plasma neurofilament light chain (pNfL) levels
Number of subjects: 4385
Study: 35315076

Group type: EXPERIMENTAL
Intervention: Charge Your Brainzzz intervention
Number of subjects: 972

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 972
Study: 33712267

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 16446

Group type: COMPARATOR
Intervention: Gemcitabine/nab‐paclitaxel (Gem/NabP)
Number of subjects: 16446

Group type: EXPERIMENTAL
Intervention: Second-line therapy with Gem/NabP or FOLFIRINOX
Number of subjects: 16446
Study: 32990370

Group type: EXPERIMENTAL
Intervention: 20% aluminum sesquichlorohydrate (AS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 20% aluminum chloride (AC)
Number of subjects: 20
Study: 35311753

Group type: EXPERIMENTAL
Intervention: Closed-incision negative-pressure wound therapy for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular dressings (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Closed-incision negative-pressure wound therapy
Number of subjects: 60